佳兆業健康(00876.HK)2020年營收達1.84億港元,第二家運動康復診所正式開業
格隆匯 3 月 24日丨佳兆業健康(00876.HK)公佈年度業績,截至2020年12月31日止年度,公司收益為1.84億港元,毛利為8996.3萬港元。
集團從事義齒業務,包括於海外和本地銷售及生產義齒,包括牙冠及牙橋、可拆式之全部及部份義齒、植體及金屬牙冠。於2020年12月31日,來自義齒業務的收益約為1.80億港元。
集團業務一向致力投資於研究及專門知識。年內,研究及開發支出為2040萬港元,反映管理層就義齒業務投資未來科技之決心及願景。另一方面,已收到市政府為數440萬港元的資助及獎勵,嘉許集團不斷努力於義齒範疇技術及專門知識的研究及開發。
集團於2018年透過收購公共健康及醫療服務之業佳有限公司參與樹蘭專案從事健康行業,並於2019年動工建設一間醫院。樹蘭專案使得集團將能滲進健康行業之前線,直接應對及識別病人之需要。此舉亦將有助於健康行業之投資決定,同時為集團建立市場聲譽。該收購事項預期將為集團現有業務帶來協同效應,相信集團之健康板塊業務可憑藉共用於該專案中將予興建之該醫院之資源及聲譽,進一步立足於長三角地區。
集團從事運動康復領域,主要以運動損傷、術後康復、慢性疼痛為主,引入德國MTT運動康復技術,第一家運動康復診所(深圳醫佳普通專科門診部)於2019年10月開業運營,截至2020年12月31日,來自門診部的收益約為344萬元人民幣,第二家運動康復診所(深圳佳醫普通專科門診部)於2021年1月26日正式開業運營。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.